Abstract

Healthcare resource utilization following ustekinumab initiation among bio-naïve Canadian patients with moderately-to-severely active Crohn's disease

Dig Liver Dis. 2024 Oct;56(10):1690-1697. doi: 10.1016/j.dld.2024.04.017.Epub 2024 May 31.

Talat Bessissow 1Neeraj Narula 2Christopher Ma 3Tracy S H In 4Eneda Pone 4Maria Eberg 5Vipul Jairath 6Canadian IBD Research Consortium

 
     

Author information

1Division of Gastroenterology, Department of Medicine, McGill University Health Centre, Montreal, QC, Canada. Electronic address: talat.bessissow@mcgill.ca.

2McMaster University, Hamilton, ON, Canada.

3University of Calgary, Calgary, AB, Canada.

4Janssen Inc., Toronto, ON, Canada.

5IQVIA Solutions Canada Inc., Kirkland, QC, Canada.

6Western University, London, ON, Canada.

Abstract

Background/aims: Real-world healthcare resource utilization (HCRU) of bio-naïve patients with Crohn's disease (CD) receiving ustekinumab was assessed.

Methods: A multicentre, retrospective chart review study of bio-naïve Canadian adult patients with moderately-to-severely active CD treated with ustekinumab was conducted. CD-related HCRU (i.e., surgery, hospitalization, or emergency room [ER] visits) was evaluated at Months 4, 6, and 12 post-ustekinumab initiation, and associated costs were sourced from a provincial database. Proportion of patients with HCRU events and ustekinumab persistence were summarized at each timepoint. Paired analysis compared HCRU events and associated costs incurred by the same patient whilst in remission vs. when not in remission.

Results: By Month 12, 11.1 % (17/153) of patients had record(s) of any CD-related HCRU event, with ER visits being the most common (7.7 %; 12/155). Hospitalization had the highest average cost (CAD $436.10; SD $2,089.25) across all patients, accounting for 82.2 % of the mean total annual cost/patient (CAD $530.47; SD $2,229.92). While in remission, ≤5 % of patients experienced some healthcare encounter, compared with 7 % when not in remission (P = 0.289). Finally, 93.5 % of patients persisted on ustekinumab at Month 12.

Conclusions: HCRU rates and associated total annual costs were lower for bio-naïve CD patients receiving ustekinumab, and when patients were in remission. Most patients continued with ustekinumab at Month 12.

© Copyright 2013-2025 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.